These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27067607)

  • 21. Solid-state characterization of amorphous and mesomorphous calcium ketoprofen.
    Atassi F; Mao C; Masadeh AS; Byrn SR
    J Pharm Sci; 2010 Sep; 99(9):3684-97. PubMed ID: 19780126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure and physical stability of hydrates and thermotropic mesophase of calcium benzoate.
    Terakita A; Byrn SR
    J Pharm Sci; 2006 May; 95(5):1162-72. PubMed ID: 16570305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward understanding the evolution of griseofulvin crystal structure to a mesophase after cryogenic milling.
    Feng T; Bates S; Carvajal MT
    Int J Pharm; 2009 Feb; 367(1-2):16-9. PubMed ID: 19013224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlling molecular transport and sustained drug release in lipid-based liquid crystalline mesophases.
    Zabara A; Mezzenga R
    J Control Release; 2014 Aug; 188():31-43. PubMed ID: 24910192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating the influence of morphology in the dynamical behavior of semicrystalline Triton X-100: insights in the detection/nondetection of the α'-process.
    Merino EG; Danéde F; Derrollez P; Dias CJ; Viciosa MT; Correia NT; Dionísio M
    J Phys Chem B; 2013 Aug; 117(33):9793-805. PubMed ID: 23937121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lyotropic liquid crystal to soft mesocrystal transformation in hydrated salt-surfactant mixtures.
    Albayrak C; Barım G; Dag Ö
    Chemistry; 2013 Oct; 19(44):15026-35. PubMed ID: 24105762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin.
    Zhang F; Aaltonen J; Tian F; Saville DJ; Rades T
    Eur J Pharm Biopharm; 2009 Jan; 71(1):64-70. PubMed ID: 18703139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tuning in-meso-crystallized lysozyme polymorphism by lyotropic liquid crystal symmetry.
    Zabara A; Amar-Yuli I; Mezzenga R
    Langmuir; 2011 May; 27(10):6418-25. PubMed ID: 21506575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Water clusters in amorphous pharmaceuticals.
    Authelin JR; MacKenzie AP; Rasmussen DH; Shalaev EY
    J Pharm Sci; 2014 Sep; 103(9):2663-2672. PubMed ID: 24824578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of molecular structure on X-ray diffraction in uniaxial and biaxial phases of thermotropic liquid crystals.
    Acharya BR; Kang SW; Prasad V; Kumar S
    J Phys Chem B; 2009 Mar; 113(12):3845-52. PubMed ID: 19296702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topological Ordering of Memory Glass on Extended Length Scales.
    Zhu SC; Chen GW; Zhang D; Xu L; Liu ZP; Mao HK; Hu Q
    J Am Chem Soc; 2022 Apr; 144(16):7414-7421. PubMed ID: 35420809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local mobility in amorphous pharmaceuticals--characterization and implications on stability.
    Bhattacharya S; Suryanarayanan R
    J Pharm Sci; 2009 Sep; 98(9):2935-53. PubMed ID: 19499564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mobility in raffinose in the crystalline pentahydrate form and in the amorphous anhydrous form.
    Moura Ramos JJ; Pinto SS; Diogo HP
    Pharm Res; 2005 Jul; 22(7):1142-8. PubMed ID: 16028015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural description of the marketed form of valsartan: A crystalline mesophase characterized by nanocrystals and conformational disorder.
    Guinet Y; Paccou L; Danède F; Derollez P; Hédoux A
    Int J Pharm; 2017 Jun; 526(1-2):209-216. PubMed ID: 28473234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vibrational density of states of triphenylene based discotic liquid crystals: dependence on the length of the alkyl chain.
    Krause C; Zorn R; Emmerling F; Falkenhagen J; Frick B; Huber P; Schönhals A
    Phys Chem Chem Phys; 2014 Apr; 16(16):7324-33. PubMed ID: 24623092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An investigation into the crystallization tendency/kinetics of amorphous active pharmaceutical ingredients: A case study with dipyridamole and cinnarizine.
    Baghel S; Cathcart H; Redington W; O'Reilly NJ
    Eur J Pharm Biopharm; 2016 Jul; 104():59-71. PubMed ID: 27108783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic vapor sorption as a tool for characterization and quantification of amorphous content in predominantly crystalline materials.
    Sheokand S; Modi SR; Bansal AK
    J Pharm Sci; 2014 Nov; 103(11):3364-3376. PubMed ID: 25213429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of low molecular weight excipient octaacetylmaltose on the liquid crystalline ordering and molecular dynamics in the supercooled liquid and glassy state of itraconazole.
    Kaminska E; Tarnacka M; Kolodziejczyk K; Dulski M; Zakowiecki D; Hawelek L; Adrjanowicz K; Zych M; Garbacz G; Kaminski K
    Eur J Pharm Biopharm; 2014 Nov; 88(3):1094-104. PubMed ID: 25460155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of compaction-induced crystallinity reduction of a pharmaceutical solid using 19F solid-state NMR and powder X-ray diffraction.
    Liu J; Nagapudi K; Kiang YH; Martinez E; Jona J
    Drug Dev Ind Pharm; 2009 Aug; 35(8):969-75. PubMed ID: 19360510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physical stability of the amorphous anticholesterol agent (ezetimibe): the role of molecular mobility.
    Knapik J; Wojnarowska Z; Grzybowska K; Hawelek L; Sawicki W; Wlodarski K; Markowski J; Paluch M
    Mol Pharm; 2014 Nov; 11(11):4280-90. PubMed ID: 25310722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.